Rapport Therapeutics (RAPP) Capital Expenditures (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Capital Expenditures data on file, last reported at $86000.0 in Q1 2026.

• On a quarterly basis, Capital Expenditures fell 70.45% year-over-year to $86000.0 in Q1 2026; TTM through Mar 2026 was $411000.0, a 74.69% decrease from a year earlier, with the FY2025 full-year figure at $616000.0, down 74.39% from the prior year.
• Capital Expenditures for Q1 2026 stood at $86000.0, down from $169000.0 in the prior quarter.
• Over the last five years, Capital Expenditures for RAPP reached as high as $1.4 million in Q4 2023 and fell as low as $22000.0 in Q2 2025.
• Historically, Capital Expenditures has averaged $417818.2 across 4 years, with a median of $169000.0 in 2025.
• Across the five-year window, Capital Expenditures soared 169.23% in 2024 and plunged 97.72% in 2025, its largest moves.
• Year by year, Capital Expenditures stood at $1.4 million in 2023, then plunged by 84.27% to $226000.0 in 2024, then declined by 25.22% to $169000.0 in 2025, then tumbled by 49.11% to $86000.0 in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $86000.0 in Q1 2026, $169000.0 in Q4 2025, and $134000.0 in Q3 2025.